Table 3.

Selected grade 3/4 treatment-related adverse events commonly reported with vascular endothelial growth factor inhibitors and laboratory test change by dose (all treated patients)

	180 mg	320 mg	600 mg	800 mg C	800 mg I	1000 mg	400 mg b.i.d.
	n = 3	n = 14	n = 3	n = 20	n = 11	n = 4	n = 13
AEa related to study drug
Fatigue	0 (0)	3 (21)	0 (0)	3 (15)	0 (0)	1 (25)	2 (15)
Hypertension	0 (0)	0 (0)	0 (0)	3 (15)	0 (0)	1 (25)	1 (8)
Diarrhea	0 (0)	0 (0)	0 (0)	2 (10)	1 (9)	0 (0)	0 (0)
Dizziness	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	1 (8)
Nausea	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)
Vomiting	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)
Laboratory testsb
ALT increased	0 (0)	0 (0)	1 (33)	3 (15)	0 (0)	2 (50)	1 (8)
AST increased	0 (0)	1 (7)	1 (33)	1 (5)	1 (9)	0 (0)	0 (0)
Bilirubin increased	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Hyponatremia	1 (33)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)

^aNational Cancer Institute–Common Terminology Criteria for AEs, v 3.

^bGrade increase from baseline.

AE, adverse event; C, continuous; I, intermittent; ALT, alanine aminotransferase; AST, aspartate aminotransferase.